Literature DB >> 19447901

Long-term hormone replacement therapy preserves bone mineral density in Turner syndrome.

Line Cleemann1, Britta E Hjerrild, Anna L Lauridsen, Lene Heickendorff, Jens S Christiansen, Leif Mosekilde, Claus H Gravholt.   

Abstract

CONTEXT: Reduced bone mineral density (BMD) and increased risk of fractures are present in many women with Turner syndrome (TS).
OBJECTIVE: Examine longitudinal changes in BMD in TS and relate changes to biochemical parameters.
DESIGN: Prospective, pragmatic, and observational study. Examinations at baseline and follow-up (5.9+/-0.7 years).
SETTING: Tertiary hospital. PARTICIPANTS: Fifty-four women with TS (43.0+/-9.95 years). Interventions Hormone replacement therapy (HRT) and calcium and vitamin D supplementation. Main outcome measures BMD (g/cm(2)) measured at lumbar spine, hip, and the non-dominant forearm. Bone formation and resorption markers, sex hormones, IGF1, and maximal oxygen uptake.
RESULTS: At follow-up, forearm BMD, radius ultradistal BMD, and hip BMD remained unchanged, radius 1/3 BMD declined (0.601+/-0.059 vs 0.592+/-0.059, P=0.03), while spine BMD increased (0.972+/-0.139 vs 1.010+/-0.144, P<0.0005). Bone formation markers did not change over time in TS. Bone resorption markers decreased over time in TS. Testosterone, IGF1, and maximal oxygen uptake was significantly reduced in TS.
CONCLUSION: Longitudinal changes in BMD in TS were slight. BMD can be maintained at most sites in well-informed women with TS, being encouraged to maintain a healthy lifestyle, including HRT and intake of calcium and vitamin D.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447901     DOI: 10.1530/EJE-09-0020

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Association between ER-α polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment--a pilot study.

Authors:  Elżbieta Sowińska-Przepiera; Elżbieta Andrysiak-Mamos; Kornel Chełstowski; Grażyna Adler; Zbigniew Friebe; Anhelli Syrenicz
Journal:  J Bone Miner Metab       Date:  2011-01-27       Impact factor: 2.626

Review 2.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

Review 3.  The patient with Turner syndrome: puberty and medical management concerns.

Authors:  Luisa Gonzalez; Selma Feldman Witchel
Journal:  Fertil Steril       Date:  2012-08-09       Impact factor: 7.329

4.  Body composition and bone mineral status in patients with Turner syndrome.

Authors:  Kun Shi; Li Liu; Yao-Juan He; Duan Li; Lian-Xiong Yuan; Gendie E Lash; Li Li
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

Review 5.  Bridging the gap: metabolic and endocrine care of patients during transition.

Authors:  Anita Hokken-Koelega; Aart-Jan van der Lely; Berthold Hauffa; Gabriele Häusler; Gudmundur Johannsson; Mohamad Maghnie; Jesús Argente; Jean DeSchepper; Helena Gleeson; John W Gregory; Charlotte Höybye; Fahrettin Keleştimur; Anton Luger; Hermann L Müller; Sebastian Neggers; Vera Popovic-Brkic; Eleonora Porcu; Lars Sävendahl; Stephen Shalet; Bessie Spiliotis; Maithé Tauber
Journal:  Endocr Connect       Date:  2016-11-01       Impact factor: 3.335

Review 6.  [Turner syndrome and genetic polymorphism: a systematic review].

Authors:  Alessandra Bernadete Trovó de Marqui
Journal:  Rev Paul Pediatr       Date:  2015-02-18

Review 7.  Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies.

Authors:  Maria Felicia Faienza; Annamaria Ventura; Silvia Colucci; Luciano Cavallo; Maria Grano; Giacomina Brunetti
Journal:  Front Endocrinol (Lausanne)       Date:  2016-04-26       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.